Syndesis Health
19.9.2023 15:14:18 CEST | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / September 19, 2023 / InSyBio, a leading biotechnology company that has developed a suite of advanced AI tools for biomarker discovery in clinical and multi-omics data, has announced a strategic partnership with Syndesis Health, a leader in global real-world evidence. The partnership aims to leverage the clinical and genomic data on Syntium, Syndesis' data platform of global healthcare data, to accelerate research and development in several therapeutic areas, including cardiovascular health, oncology, and rare diseases.
The importance of biomarkers
Biomarkers are body characteristics that can be measured, such as the biological molecules found in bodily fluids or tissues, including DNA, antibodies, proteins, or other smaller molecules. They are necessary to predict the effectiveness of drugs and patient outcomes; however, biomarker discovery is a very complex and costly process that often results in poor or inaccurate outcomes due to the use of disparate tools and datasets, and the high complexity of high-throughput -omics data.
InSyBio's platform simplifies and accelerates the process of biomarker discovery by providing a single, highly accurate, and effective processing pipeline that uses machine learning to analyze biodata. Syntium's longitudinal datasets, which include clinical, genomic, and other data, are ideal for applying InSyBio's suite of tools in biomarker discovery. Combining Syntium data with InSyBio's platform will create a unique opportunity for biopharma and diagnostic companies to uncover breakthrough discoveries with the potential to vastly improve global patient outcomes.
"Precision medicine is still in its infancy and many patients are misdiagnosed or do not get the most beneficial treatment for them. The wealth of Syntium's data sets when harnessed by our automatic AI-driven technology holds the potential to upend the medical field practices, and highly impact overall healthcare quality at national and international levels. We are looking forward to working with the innovative team of Syndesis Health," said Labros Digonis, InSyBio CEO.
"We are incredibly excited to embark on this partnership with InSyBio to enable biomarker discovery for cutting-edge healthcare innovation," said Josh Sutton, Syndesis Health CEO. "Together we seek to raise the bar for global health research and innovation in service of patients worldwide."
About Syndesis Health
Syndesis Health is the data and technology catalyst to a multi-continent network of healthcare and life sciences organizations. Its primary aim is to enhance global health outcomes and equity through its secure data platform, Syntium, and the Syndesis Health Network, a member community promoting research collaboration, information sharing, and access to common tools.
About InSyBio
InSyBio is an international pioneer biotechnology company revolutionizing the medical field through targeted biomarker discovery, highly accurate predictive analytics and the development of personalization tests for drugs. Its solutions provide the R&D departments of Pharma and Research Institutes with the means to meet their most challenging research and innovation goals. This is done through a sophisticated, software-as-a-service, machine learning platform, which comprehensively integrates multi-omics and clinical data, thus reducing the number of samples and additional validation experiments needed.
Contact Information
Leah Patterson
Chief Marketing Officer
leah.patterson@syndesis.com
+1.646.274.1420
SOURCE: Syndesis Health
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/785152/syndesis-health-and-insybio-partner-in-predictive-modelling-and-biomarker-discovery
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications7.5.2026 22:05:00 CEST | Press release
Integrated lidar and modular drone platforms enable scalable autonomy, mapping, and navigation across complex real-world environments REDMOND, WA AND EINDHOVEN, THE NETHERLANDS / ACCESS Newswire / May 7, 2026 / MicroVision, Inc., (Nasdaq:MVIS), a leader in advanced perception solutions, today announced the signing of a Memorandum of Understanding (MoU) with Avular Innovations B.V. to integrate their technologies and accelerate the development of next-generation autonomous systems for civil infrastructure and global commercial applications. By combining MicroVision's high-performance, solid-state lidar, optimized for reduced energy usage and increased operational efficiency, with Avular's modular drone platforms and system integration expertise, the companies are creating a flexible, scalable solution designed to address real-world operational challenges across global markets. The collaboration focuses on delivering advanced capabilities, including autonomous mission execution in GPS-de
Innodata Reports Record First Quarter 2026 Results7.5.2026 22:05:00 CEST | Press release
Revenue Up 54% Year-Over-Year, Beats Consensus by 18% Adjusted EBITDA of $25.0 Million Beats Consensus by 139%; Adjusted Gross Margin Expands to 47% Raises Full-Year 2026 Revenue Growth Guidance to ~40% or More, Up From ~35% or More Announces New Engagements With Big Tech Company Expected to Generate Approximately $51 Million of Revenue in 2026 NEW YORK, NY / ACCESS Newswire / May 7, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2026. Revenue of $90.1 million, representing 54% year-over-year revenue growth. Adjusted Gross Profit of $42.6 million, representing Adjusted Gross Margin of 47%.* Adjusted EBITDA of $25.0 million, or 28% of revenue, an increase of $12.3 million from $12.7 million in the same period last year.* Net income of $14.9 million, or $0.46 per basic share and $0.42 per diluted share, compared to net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, in the same period last year. Cash, cash equ
Ostathi, Operated by UniHouse, Pioneers the Middle East's First Digital Infrastructure Linking Structured Workforce Development to Verified Income7.5.2026 18:30:00 CEST | Press release
World Bank and Jordan Ministry of Digital Economy-Funded Programme - Delivering the Region's First Auditable Connection Between Structured Capacity Development and Verified Income LONDON, UK / ACCESS Newswire / May 7, 2026 / Ostathi, owned and operated by UniHouse, today announced the live national deployment of a proprietary digital ledger infrastructure in Jordan - a first-of-its-kind system across the Middle East and Africa that connects an individual's structured capacity development, competency certification, gig economy and marketplace participation, and income generation into a single, auditable digital chain, integrated directly with regulated national fintech platforms. Ostathi Jordan - live deployment under the World Bank Youth, Technology and Jobs programme in partnership with Jordan's Ministry of Digital Economy and Entrepreneurship. The deployment is funded under the World Bank Youth, Technology and Jobs (YTJ) Project in partnership with Jordan's Ministry of Digital Econom
Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook7.5.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2026. First Quarter 2026 Net sales of $156.1 million, up 36.1% compared to the prior year's quarter. Net income of $11.1 million, compared to $15.3 million for the prior year's quarter, primarily resulting from higher interest, higher non-cash amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Diluted earnings per share of $0.12 compared to $0.16 for the prior year's quarter, primarily resulting from higher interest, higher amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Adjusted EBITDA of $63.2 million, up 46.6% compared to the prior year's quarter. Net income margin of 7.1% compared t
Able Device Introduces SIMbae(TM), Enabling Deterministic AI Execution at the Identity Layer7.5.2026 14:15:00 CEST | Press release
From Connectivity Management to Execution. AI predicts. SIMbae enforces. RALEIGH, NC / ACCESS Newswire / May 7, 2026 / Able Device today announced a major evolution of its SIMbae™ technology, introducing AI-driven connectivity execution directly within the SIM/eSIM secure element - transforming the SIM into a deterministic enforcement engine for intelligent mobile networks. Across the telecom industry, artificial intelligence is rapidly being adopted to analyze network data, predict device behavior, and recommend connectivity optimizations. However, a critical gap remains: while AI generates insights, there has been no universal mechanism to enforce those decisions consistently across devices, networks, and geographies. SIMbae closes that gap. By embedding deterministic policy execution inside the SIM - the most widely deployed secure element - SIMbae turns AI insight into real-world device behavior without requiring applications or device firmware changes. AI predicts. SIMbae enforces
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom